Abemaciclib Breast Cancer Survival – Clinical Trial Results
Hope on the Horizon: Abemaciclib Extends Life for High-Risk Early breast Cancer Patients
For women facing a daunting diagnosis of hormone receptor-positive (HR+), HER2-negative, node-positive, high-risk early breast cancer, recent news offers a beacon of hope. A groundbreaking clinical trial has demonstrated that adding abemaciclib (Verzenio) to standard endocrine therapy (ET) significantly improves overall survival (OS) compared to ET alone. This finding reinforces abemaciclib as the standard of care and underscores the urgency of ensuring access to this treatment for all eligible patients.
Breast cancer remains a notable global health challenge, accounting for nearly 666,000 deaths worldwide in 2022. Among the various subtypes, HR+, HER2- breast cancer is the moast common, representing approximately 70% of all cases. While early detection often leads to a favorable prognosis, women with high-risk characteristics face a threefold increased risk of recurrence. These high-risk factors include cancer that has spread to the lymph nodes, a large tumor size, and a high tumor grade.
The phase 3 monarchE clinical trial, a global, multicenter study, enrolled 5,637 adults with HR+, HER2-, node-positive early breast cancer at high risk of recurrence. Participants were divided into two groups: one receiving abemaciclib in addition to standard ET, and the othre receiving ET alone. the study revealed that the addition of abemaciclib led to a statistically significant and clinically meaningful advancement in overall survival.
“Preventing disease relapse and helping patients live longer is the ultimate goal,” stated Jacob Van Naarden, executive vice president and president of Lilly Oncology. “Achieving a statistically significant OS benefit with just two years of [abemaciclib] therapy reinforces its differentiated profile in high-risk HR-positive, HER2-negative early breast cancer.”
Abemaciclib, a CDK4/6 inhibitor, works by blocking proteins that promote cancer cell growth.It was initially approved for advanced or metastatic breast cancer and later received FDA approval in March 2023 for the adjuvant treatment of high-risk early breast cancer.The drug is administered orally twice daily.
“These data validate [abemaciclib] as the standard-of-care for patients with node-positive, high-risk disease and increase the urgency to ensure all eligible patients are treated,” added Naarden.
What does this mean for patients?
The results of the monarchE trial offer renewed hope for women diagnosed with HR+, HER2-, node-positive, high-risk early breast cancer. Abemaciclib, in combination with endocrine therapy, has the potential